News
Icosabutate latest phase 2b interim data show significant decreases in NASH and fibrosis biomarkers independent of fibrosis stage and disease severity
NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, today announces the presentation of new interim data from the Phase 2b ICONA trial during The Liver Meeting Digital Experience 2021 (TLMdX) of the American Association for the Study
Read More
Cambridge Epigenetix raises $88 million Series D financing to advance best-in-class DNA sequencing technology platform
Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionizing genome sequencing, has announced the signing of an $88 million Series D financing, bringing the total funds raised to date to $146 million. Temasek led the Series D round with participation from new investors including Third Point and existing
Read More
Novadip Biosciences announces EUR 19 million Series B financing backed by international investors
Novadip Biosciences (“Novadip” or “the Company”), a clinical stage company developing treatments to regenerate impaired tissue in patients with significant unmet medical needs, has announced that it has raised €19 million in the first close of a Series B financing, which was co-led by new investor CR-CP Life Science Fund,
Read More
VUV Analytics, Inc. Introduces the LUMA™ Multi-Channel Vacuum Ultraviolet Absorbance Detector
VUV Analytics, Inc. has introduced the VUV LUMA Multi-Channel Vacuum Ultraviolet Absorbance Detector, providing best-in-class detector sensitivity, universal detection, and selectivity that seamlessly integrates into existing laboratory workflows. “LUMA represents the next logical step in our long-term product strategy,” said Clark Jernigan, CEO of VUV Analytics. “Since the introduction of our
Read More
BrightVolt raises $16 million in Series B funding led by New Science Ventures and Caterpillar Venture Capital Inc.
BrightVolt, Inc., a global leader in the design, development, and manufacturing of safe, high energy and low cost solid-state Lithium-Ion batteries has successfully closed the first tranche of a $16M Series B financing round with significant investments by New Science Ventures (NSV) and Caterpillar Venture Capital Inc. (Caterpillar). Fresh funds
Read More
Ventyx Biosciences announces key appointments and closing of $51m Series B financing
Ventyx Biosciences, Inc. (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, has announced the appointment of Sheila Gujrathi, M.D. to the Board of Directors as Executive Chair and Jörn Drappa, M.D., Ph.D. as Chief
Read More
VORAGO Technologies announces low-cost and immediately available rad-tolerant hi-rel MCU for New Space, LEO market
VORAGO Technologies (https://voragotech.com) has announced a product portfolio expansion to include a new radiation-tolerant Arm® Cortex-M0 MCU, VA10805, as a cost-competitive and high reliability solution for LEO, New Space, SmallSat and CubeSat markets. "As commercialization of space continues to grow, so does the need for reliable, affordable, and immediately available
Read More
Isorg raises €16 million in Series C financing
Isorg, a pioneer in Organic Photodetectors (OPDs) and large-area image sensors, has announced a capital increase of €16M in series C financing. Two major industrial investors, Sumitomo Chemical Co. Ltd and Mitsubishi Corporation, participated in the round. Greece-based Integrated Systems Development SA and five new French investors represented by fund
Read More
Bioasis Technologies Inc and Oxyrane UK Ltd enter into a Research Collaboration
Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF), (“Bioasis”) and Oxyrane UK Ltd (“Oxyrane”) are pleased to announce the initiation of a research collaboration. Bioasis is a pre-clinical, research-stage biopharmaceutical company developing a proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS
Read More
Resolve Therapeutics receives FDA approval to initiate Phase 2 clinical trial of RSLV-132 in long covid patients
Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced that the US Food and Drug Administration has approved a New Investigational Drug application for RSLV-132 to initiate a phase 2 clinical trial in patients with long covid. It is estimated that up to 30% of patients
Read More
Zeotap launches Google Customer Match integration to drive addressability in a post-cookie world
Zeotap, the leading Customer Data Platform, has launched a new integration with Google Customer Match, enabling marketers to leverage their first-party data to engage audiences at scale across Google Search, Shopping, Gmail, YouTube and Display. In doing so, the new integration provides an important solution to addressability when third-party cookies
Read More
CanCell Therapeutics partners with Ovizio to improve monitoring of CAR-T cell production
Ovizio Imaging Systems, a manufacturer of cell analyzers for advanced monitoring in the bioprocessing market, and CanCell Therapeutics, an early-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that they will enter into a collaboration to further improve the monitoring of CAR-T cell-therapy manufacturing. The partnership
Read More